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Background
The FDA approved drug Efavirenz is a Non-Nucleoside
Reverse Transcriptase Inhibitor (NNRTI) successful first
line drug of choice in Highly Active Anti-Retroviral
Therapy (HAART) for treatment of HIV and AIDS. It is
poorly water soluble drug (10 g/ml) with 40-45% of
bioavailability and administered as high doses 600-800
mg/day. Increase in solubility can enhance bioavailabil-
ity; providing reduction of dose, resistance and harmful
side effects.
Methods
Efavirenz nanoparticles are developed using methacry-
late polymers (Eudragit E100) by emulsion solvent eva-
poration method (1:0.5, 1:1, 1:2 and 2:1 ratios) and the
in-vitro evaluations such as particle size, morphology,
solubility changes, drug release, compatibility and cyto-
toxicity tests are carried out.
Results
The particle size of 99-200 nm with narrow size distri-
bution and surface charge (-52 V) shows high stability.
The formulation with entrapment efficiency (75-90%)
shows higher drug release profile 95-100% within 1 hour
compared to 23%-58% of pure drug in water, 0.1N HCl
and phosphate buffer pH 7.4 media. The DSC, TG-DSC,
powder XRD and SEM morphology results reveal that
there is solid transition from crystalline structure to
amorphous state, which supports the solubility enhance-
ment. The FT-IR gives the compatibility results for drug
with other excipients. The Efavirenz nanoparticles
subjected for in-vitro cytotoxicity and cell uptake studies
using monocytes / macrophages (THP-1) proved better
uptake (Flocytometry and Confocal microscope) of
nanoparticles than free drug.
Conclusion
The solubility enhancement due to nanosizing helps in
hastening the drug release and also increasing cell
uptake, which helps in attaining high bioavailability with
low dose of Efavirenz.
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